remdesivir

Study identifies Covid-19 patients with mutations indicating remdesivir resistance
Study identifies Covid-19 patients with mutations indicating remdesivir resistance
Endpoints
Gilead Sciences
remdesivir
COVID-19
Flag link:
Gilead collects 5th priority review voucher as public advocacy group urged the company to relinquish it
Gilead collects 5th priority review voucher as public advocacy group urged the company to relinquish it
Endpoints
Gilead Sciences
COVID-19
remdesivir
priority review
Flag link:
Gilead’s Covid-19 treatment Veklury props up first quarter gains amid $2.7B Trodelvy writedown
Gilead’s Covid-19 treatment Veklury props up first quarter gains amid $2.7B Trodelvy writedown
Endpoints
Gilead Sciences
Veklury
remdesivir
earnings
Trodelvy
Flag link:
FDA approves first COVID treatment for children under 12
FDA approves first COVID treatment for children under 12
Axios
FDA
Gilead Sciences
Veklury
remdesivir
pediatric
Flag link:
Gilead touts analysis showing COVID antiviral Veklury performs best when given early in illness
Gilead touts analysis showing COVID antiviral Veklury performs best when given early in illness
Fierce Pharma
Gilead Sciences
Veklury
COVID-19
remdesivir
WHO
Flag link:
Despite strong quarter, some wonder how long Gilead can rely on coronavirus drug
Despite strong quarter, some wonder how long Gilead can rely on coronavirus drug
BioPharma Dive
Gilead Sciences
earnings
Veklury
remdesivir
COVID-19
Flag link:
Remdesivir reduces Covid hospitalizations when given early, study shows
Remdesivir reduces Covid hospitalizations when given early, study shows
Stat
Gilead Sciences
remdesivir
COVID-19
Flag link:
Oral Remdesivir Could Lower COVID Hospitalizations, Preclinical Study Says
Oral Remdesivir Could Lower COVID Hospitalizations, Preclinical Study Says
BioSpace
Gilead Sciences
remdesivir
COVID-19
Flag link:
Real-world remdesivir data add to body of evidence for Gilead Sciences Covid-19 drug
Real-world remdesivir data add to body of evidence for Gilead Sciences Covid-19 drug
MedCity News
Gilead Sciences
remdesivir
COVID-19
real world data
real world evidence
RWE
Flag link:
Gilead stops Veklury study, citing enrollment challenges, changing treatment
Gilead stops Veklury study, citing enrollment challenges, changing treatment
BioPharma Dive
Gilead Sciences
COVID-19
remdesivir
Veklury
clinical trials
Flag link:
India axes exports of Gilead Sciences' remdesivir, plots boost to local production as COVID cases mount: reports
India axes exports of Gilead Sciences' remdesivir, plots boost to local production as COVID cases mount: reports
Fierce Pharma
India
drug manufacturing
Gilead Sciences
remdesivir
COVID-19
Flag link:
Pharma Gilead has sole rights to COVID-19 blockbuster Veklury, GAO concludes
Pharma Gilead has sole rights to COVID-19 blockbuster Veklury, GAO concludes
Fierce Pharma
Gilead Sciences
remdesivir
Veklury
GAO
COVID-19
Flag link:
Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead — Boosted by Taxpayers
Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead — Boosted by Taxpayers
KHN
Gilead Sciences
remdesivir
COVID-19
Flag link:
Cancer drug derived from sea squirts outperforms remdesivir in COVID-19 preclinical models
Cancer drug derived from sea squirts outperforms remdesivir in COVID-19 preclinical models
Fierce Biotech
PharmaMar
plitidepsin
Aplidin
remdesivir
COVID-19
Flag link:
Gilead says Veklury should work against COVID-19 variants
Gilead says Veklury should work against COVID-19 variants
Pharmaforum
Gilead Sciences
Veklury
remdesivir
B.1.1.7 variant
Flag link:
Gilead Updates 2020 Guidance with Post-Holiday COVID-19 Spike
Gilead Updates 2020 Guidance with Post-Holiday COVID-19 Spike
BioSpace
Gilead Sciences
COVID-19
remdesivir
Veklury
Flag link:
Could a lymphoma drug work better against COVID-19 than Gilead's remdesivir?
Could a lymphoma drug work better against COVID-19 than Gilead's remdesivir?
Fierce Biotech
China
COVID-19
Gilead Sciences
remdesivir
Folotyn
Acrotech Biopharma
Flag link:
Fierce Pharma's top 2020 marketing stories pack pandemic punch to digital, reputation and drug launches
Fierce Pharma's top 2020 marketing stories pack pandemic punch to digital, reputation and drug launches
Fierce Pharma
pharma marketing
drug pricing
COVID-19
pandemic
remdesivir
Gilead Sciences
HIV
PrEP
Pfizer
Flag link:
Where Will Gilead Sciences Be in 1 Year?
Where Will Gilead Sciences Be in 1 Year?
Motley Fool
Gilead Sciences
Veklury
remdesivir
COVID-19
Flag link:
WHO's decision to reject remdesivir based on flawed study, health experts say
WHO's decision to reject remdesivir based on flawed study, health experts say
Beckers Hospital Review
WHO
Gilead Sciences
remdesivir
COVID-19
Flag link:

Pages